A combination of Roche's recently launched PD-L1 inhibitor, Tecentriq (atezolizumab), and its blockbuster selling anti-VEGF anticancer, Avastin (bevacizumab) was associated with a 26% reduction in the risk of advanced or metastatic renal cell cancer worsening or leading to death, in patients who expressed the PD-L1 protein in the IMmotion151 study, Roche announced on Feb. 6.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?